Objective. The concept of neuromodulation via the use of spinal cord stimulators (SCS) was first established over forty years ago. Since then, its popularity has grown as numerous studies have demonstrated its utility to reduce chronic pain, improve patient function, and reduce long-term health care costs. The aim of this study was to update the pain medicine community on the evolution of SCS practice trends in academic centers.
Introduction
In 1967, based upon the "gate theory" proposed by Melzack and Wall, Shealy et al. implanted the first spinal cord stimulator (SCS) device and demonstrated that pain signal transmission can be inhibited by electrical stimulation [1] . Since then, SCS technology and implementation have advanced a great deal, with more than 14,000 SCS implantations performed worldwide each year [2] . The most commonly reported indication for SCS use in the United States is failed back surgery syndrome (FBSS); however, it has been used successfully to treat complex regional pain syndrome (CRPS), diabetic neuropathy, radiculopathy, phantom limb pain, spinal cord injury related pain, arachnoiditis, peripheral vascular disease, intractable abdominal pain, and recurrent angina pectoris [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Contraindications to implantation include psychological unsuitability (significant depression, anxiety, or personality disorder), non-neuropathic pain, bleeding disorders, or anticoagulation therapy [16] . The ultimate objective of spinal cord stimulation is to decrease pain that has failed more conservative therapy in order to improve patient function and quality of life.
Although this technology has been around for over 40 years, there remains a lack of uniformity with regard to practical approach, equipment utilization, and clinical training instruction. In 1999, Fanciullo et al. sought to collect data addressing these exact issues in an attempt to better understand and help guide SCS implantation practice [17] . A 34-item survey was sent out to the program directors of all 95 US Accreditation Council for Graduate Medical Education (ACGME) pain medicine fellowships. The results confirmed a high degree of variability in academic clinical practice, which underscored a lack of knowledge about the previously mentioned variables. Although the survey focused on several key components, the first was training received by pain medicine fellows. In particular, the study questioned the manner in which they garnered their skills, and whether manufacturer representatives played a role in their education. Second, technical aspects were addressed, including types of leads placed and employment of a surgeon for permanent device placement. Finally, clinical preferences were recorded, such as the normal length for SCS trials, whether patients were admitted for observation post procedure, and who adjusted device settings on follow-up.
Currently, three companies dominate the neuromodulation marketplace: Medtronic, Inc (Minneapolis, MN, USA) (the oldest), St. Jude Medical (St. Paul, MN, USA), and Boston Scientific (Natick, MA, USA). Each manufacturer's product contains certain unique characteristics. Medtronic claims that their handheld programmer is user-friendly and allows the patient to adjust their own energy requirements, as well as modulate paresthesia coverage to maximize pain relief. St. Jude Medical advertises an array of leads, paddles, steering devices, rechargeable batteries, and constant current energy deliverance. Boston Scientific maintains that they have the smallest battery and i-Sculpt technology, which allows the programmer to shift the energy from one lead to another in order to target particular areas [18] . It is important for us to realize that with the constantly changing landscape of technology, it behooves pain medicine fellowship programs to take responsibility for the proper instruction in trialing, implantation, and use of these devices. Additionally, as noted by Fanciullo et al., manufacturer representative involvement may lead to significant bias in choosing one device over another for reasons other than what is in the patient's best interest.
The aim of this study was to update the pain medicine community on the evolution of SCS practice and preferences within academic institutions over the last decade. Our goal was to obtain data, in order to better quantify current clinical trends, in an attempt to establish a consensus approach for each step involved in SCS implantation. This will aid in developing a standard of care protocol for the management of patients who may benefit from the use of an SCS.
Methods
Once an institutional review board approval was obtained, a 37-item questionnaire was constructed, which was based upon a modified version of the 1999 survey distributed by Fanciullo et al. The 93 anesthesiology pain fellowship programs and their respective program directors were identified via the official ACGME Website. Each program director was e-mailed a cover letter describing the study, along with a hyperlink providing access to the secure survey Website. Two weeks after the initial e-mail was sent, a follow-up notification was e-mailed. At week four, in conjunction with a third e-mail, a telephone call was made to each program director's secretary as a reminder for the study to be completed. At week six, non-responding institutions were contacted via a fourth e-mail and a second telephone call was made. Additionally, two responses were recorded via paper. Data collection spanned from October 2011 to March 2012. Responses that were unclear or incomplete were not interpreted or considered in the calculation of percentages. If answers were given as ranges, the averages were tallied and used in the final computations. Each program's reply was noted by their internet protocol address logged by the survey Website. Only the investigators had access to this information; however, no participant's name could be directly identified. Programs that did not respond were noted and contacted according to the previously mentioned protocol. Anonymity was sacrificed, in a few cases, in an attempt to amass as many responses as possible.
The questionnaire was constructed in three sections (Appendix 1). It consisted of some of the same questions and expanded upon others originally posed by Fanciullo et al. The first portion focused on demographics, including the number of fellows at particular centers, the number of practicing anesthesiologists, whether or not they performed SCS procedures, and if so, how many. The second segment outlined specifics related to education and procedural matters, such as the number of SCS trials/implantations performed by the anesthesia department including who is deemed the most valuable trainers of SCS implantation, manufacturer presence during implantation, success rates based on indication, and the role of psychologists in screening and follow-up. The final inquiries related to technical issues, namely length of trial time, role of manufacturer presence at trials, how leads are secured, hospital length of stay for trial and permanent implantation, parameter settings, battery and lead types, the role of surgeons during implantation, instrument revision rates, and follow-up care. (Table 1) . Manufacturer-sponsored workshops were felt to be the second most beneficial tool by 64.4% of directors. Lastly, nearly 70% of directors agreed that continuing medical education conferences were the least significant resource. Programs reported a nearly unanimous attendance by manufacturer representatives during the SCS trials and permanent implantations, with average rates of 97.96% and 97.92%, respectively. Generally, program directors were in favor of manufacturer's involvement in the training of fellows, with only 29.2% reporting they were against this practice. Furthermore, 91.84% of directors listed representatives as the primary provider for device reprogramming when indicated.
Results

Completed
SCS trials were exclusively performed as an outpatient procedure with a few programs admitting permanent implantations for overnight observation. Survey question 12 listed several medical conditions commonly treated with SCS implants, and respondents were asked to rank the frequency of utilization. Question 13 followed a similar format but focused on success rates for a given diagnosis. Both were rated on a 1-5 scale, where the lower average rating indicated more frequent use and higher success rate, respectively. The most common indication for an SCS trial was FBSS, with CRPS receiving the vast majority of second place votes ( Table 2) . FBSS was felt to have the highest 2-year success rate and received 52.08% of first place votes, followed again by CRPS, which had a large number of first place votes but had an overall higher average rating (Table 3) .
Eighty-seven percent of respondents referred to a psychologist/psychiatrist before the SCS trial. Ninety-one percent of patients received a trial preimplant, with only 2.1% proceeding to implantation the same day. Nearly 85% of practitioners felt 4-7 days were required in order to deem an SCS trial successful. Trial leads were secured to the skin by a combination of methods, including suturing (61.7%), taping (51.1%), and/or tunneling (12.8%). Cylindrical octapolar dual leads were predominantly used. The most important factor listed in battery selection was patient preference, with 77.28% of people choosing a rechargeable model. Thirty-five percent of pain physicians performed implantations independently. When requiring the assistance of a surgeon, the most frequently cited reason was to perform a laminotomy. Only 6.5% of Please rank the five most common indications for SCS trials in your Department? ("1" being the most common and "5" being the fifth most common). The most common choice for each category is displayed in bold. (N = 49). CRPS = complex regional pain syndrome; SCS = spinal cord stimulator.
patients fail intraoperative testing secondary to inadequate paresthesia coverage of the painful area (Table 4 ). This was also felt to be the most likely reason for SCS trial failure (Table 5 ). Personal experience gained from past programming based on specific patient factors, such as diagnosis, age, and involved region, was the most readily cited method to maximize paresthesia coverage.
In terms of post-procedure care, patients were generally observed every 2-4 weeks (64.44%) after implantation to calibrate settings. Once optimized, the majority (82.79%) are seen no more than four times per year. Over the patient's lifetime, lead and pocket revisions are required and were performed by physicians at a rate of 6.23% and 3.27%, respectively, on an annual basis.
Discussion
Comparing the information gathered during this study with that of Fanciullo et al. in 1999 demonstrates a great Please rank the SCS indications with the highest 2-year success rates? ("1" being the highest success rate and "5" being the fifth highest success rate). The most common choice for each category is displayed in bold. (N = 48). CRPS = complex regional pain syndrome; SCS = spinal cord stimulator. Considering the consistently increasing application of these therapies, pain fellowship programs must assume responsibility for providing proper training in order to ensure the development of competent pain management physicians in the clinical and technical aspects of SCS therapy.
A pervasive theme throughout the Fanciullo et al. study was the involvement of manufacturer representatives within the realm of SCS implementation. Engaging in relationships with these organizations raised concern for bias in selecting devices and evaluating treatment approaches for chronic pain states. These sentiments were shared by roughly 50% of the program directors, who affirmed that manufacturers should not be involved in the training of fellows. Our data support a shift in this paradigm. In general, company involvement through representatives has expanded with a majority of practitioners utilizing their services to educate the patients and fellows, set instrument parameters as directed during procedures, and provide patient follow-up care. Currently, only 29.2% of program directors view manufacturer involvement negatively. One respondent wrote: "their added resources enhances the experience of newly learning fellows and allows them to advance their skills." Their presence within the operating room has escalated from 73% to nearly 98% for both trials and implantations. Furthermore, 91% of physicians instruct manufacturers to perform device reprogramming, a task that was normally relegated to pain center staff. Keeping up with technological advancements, device complexity and novel componentry is the responsibility of physicians practicing evidence-based medicine. Enlisting the aid of representatives to share their product expertise is one element of a multifaceted approach to accomplish this goal.
Our survey sought to further explore the clinical aspects of SCS application touched upon in the previous study. The three most cited indications for trials-FBSS, CRPS, and chronic radiculopathy (Table 2 )-also had the corresponding most favorable 2-year success rates (Table 3) . These results are consistent with those found in current literature [19] and data collected in an article detailing Canadian SCS practices [20] . This supports the fact that SCS use, with a proper indication, can be of significant benefit. Moreover, experience over the last decade has demonstrated that these procedures are safe. According to respondents, trials are now performed entirely on an outpatient basis, in comparison to a 49% admission rate in 1999. On the other hand, trial length is virtually unchanged, with 4-7 days being the standard of care.
A recent prospective analysis of various chronic pain patients substantiates the use of these time frames [21] . Thirty out of 40 patients achieved a successful trial, which was judged by a 50% reduction in visual analog pain scale in 3-15 days, with a mean duration of 5.97 days.
With regard to treatment shortcomings, respondents stated that the most significant explanation for intraoperative stimulation (IOS) ( Table 4 ) and long-term trial failure (Table 5 ) was inadequate paresthesia coverage of the painful region. A study by Gordon et al. noted a scarcity of publications providing guidance on IOS parameter settings. The absence of a standardized algorithm forces physicians to attempt multiple programming combinations relying solely on empiric adjustment or personal experience [22] . In fact, respondents quoted that they often rely on a combination of experience (67%) or random trial and error (23%). The second most significant reason given for trial failure was excessive undesirable sensations. This is a consequence of unwanted stimulation of dorsal nerve roots instead of selectively targeting the dorsal columns [23] . To combat this issue, Tiede et al. trialed a high-frequency SCS system with promising results. The system generates innovative waveforms and currents that produce pain relief without paresthesias, limiting unwanted stimulation. Twenty-one of 24 patients treated for chronic back pain preferred treatment with the novel system [24] . These findings are echoed by the work of De Ridder et al., who published data on burst SCS models, which utilize intermittent packets of closely spaced, high-frequency stimuli [25] . In contrast to current tonic stimulation programs, the larger pulse width and lower amplitudes of the burst design induce subthreshold stimulation of Aβ fibers, which are implicated in the generation of paresthesias. Further research will be required to validate these approaches as a viable treatment options.
Conclusions
This investigation provides insight into current SCS practice in US academic pain medicine programs. Over the last decade, the use of SCS therapies has gained further acceptance. This is reflected in an increase in annual trials and implantations. Generally, manufacturers now play a more substantial role in patient care and fellow education. However, consistent SCS training and instruction among programs is still lacking. Data collected in this article demonstrate that continued analysis is needed in the areas of device programming to help develop disease-specific standardized algorithms. Research concentrated on improving pain coverage while limiting unwanted side effects will ultimately allow more individuals to receive effective SCS treatment. 
